

Substitute for form 1449/PTO  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
Application Number		10/769,744-Conf. #6429			
Filing Date		January 30, 2004			
First Named Inventor		Anna Helgadottir			
Art Unit		1614			
Examiner Name		S.V. Gembah			
Attorney Docket Number		30847/2051-004			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/S.G./	A21*	6,544,730	03-08-2003	Prescott et al.	
/S.G./	A22*	5,283,252	02-01-1994	Siegfried et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>2</sup> (if known)		MM-DD-YYYY			
/S.G./	B53	WO-2001/017528		03-15-2001	Nitromed Inc.		
↓	B54	WO-2004/028341 Part 1		04-29-2004	DeCode Genetics		
	B55	WO-2004/028341 Part 2		04-29-2004	DeCode Genetics		
	B56	WO-2004/028341 Part 3		04-29-2004	DeCode Genetics		
	B57	WO-2004/035741		04-29-2004	DeCode Genetics		
	B58	WO-2004/035746		04-29-2004	DeCode Genetics		
/S.G./	B59	WO-2005/027886		03-31-2005	DeCode Genetics		

Examiner Signature	Date Considered	
--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/S.G./	C135	JORGENSON et al., Ethnicity and human genetic linkage maps. <i>Am. J. Hum. Genet.</i> 76: 276-90 (2005).		
/S.G./	C136	HATZELMANN et al., Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X1005. Implications for biological regulation of 5-lipoxygenase. <i>Adv. Prost. Thromb. Leuk. Res.</i> 22: 23-31 (1994).		
/S.G./	C137	Quinoline 5-lipoxygenase inhibitors. Patent evaluation of EP 049926. <i>Curr. Opin. Ther. Pat.</i> 2: 2007-8 (1992).		
/S.G./	C138	International Search Report, European Patent Office, PCT/US2005/003312 dated January 02, 2006.		
/S.G./	C139	International Search Report, European Patent Office, PCT/US2006/012073 dated March 20, 2007.		

Examiner Signature	Date Considered	12/09/2008
--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.